相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Non-steroidal mineralocorticoid receptor antagonism for the treatment of cardiovascular and renal disease
Peter Bramlage et al.
EUROPEAN JOURNAL OF HEART FAILURE (2016)
Finerenone: a New Mineralocorticoid Receptor Antagonist Without Hyperkalemia: an Opportunity in Patients with CKD?
Hermann Haller et al.
CURRENT HYPERTENSION REPORTS (2016)
Mineralocorticoid receptor antagonists - pharmacodynamics and pharmacokinetic differences
Jun Yang et al.
CURRENT OPINION IN PHARMACOLOGY (2016)
Finerenone in heart failure: walking a fine line
Matthias Naegele et al.
EUROPEAN HEART JOURNAL (2016)
A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and/or chronic kidney disease
Gerasimos Filippatos et al.
EUROPEAN HEART JOURNAL (2016)
Steroidal and Nonsteroidal Mineralocorticoid Receptor Antagonists Cause Differential Cardiac Gene Expression in Pressure Overload-induced Cardiac Hypertrophy
Jana Grune et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2016)
Third-generation Mineralocorticoid Receptor Antagonists: Why Do We Need a Fourth?
Elise P. Gomez-Sanchez
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2016)
Masked and Nocturnal Hypertension in the ARTS-DN ABPM Sub-Study with Finerenone
L.M. Ruilope et al.
Journal of the American Society of Hypertension (2016)
CS-3150, a Novel Nonsteroidal Mineralocorticoid Receptor Antagonist, Shows Preventive and Therapeutic Effects On Renal Injury in Deoxycorticosterone Acetate/Salt-Induced Hypertensive Rats
Kiyoshi Arai et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2016)
Nonsteroidal antagonists of the mineralocorticoid receptor
Peter Kolkhof et al.
CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION (2015)
Pharmacological profile of CS-3150, a novel, highly potent and selective non-steroidal mineralocorticoid receptor antagonist
Kiyoshi Arai et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
CS-3150, a novel non-steroidal mineralocorticoid receptor antagonist, prevents hypertension and cardiorenal injury in Dahl salt-sensitive hypertensive rats
Kiyoshi Arai et al.
EUROPEAN JOURNAL OF PHARMACOLOGY (2015)
Finerenone: third-generation mineralocorticoid receptor antagonist for the treatment of heart failure and diabetic kidney disease
Licette C. Y. Liu et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2015)
Effect of Finerenone on Albuminuria in Patients With Diabetic Nephropathy A Randomized Clinical Trial
George L. Bakris et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2015)
Finerenone Impedes Aldosterone-dependent Nuclear Import of the Mineralocorticoid Receptor and Prevents Genomic Recruitment of Steroid Receptor Coactivator-1
Larbi Amazit et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2015)
Finerenone, a Novel Selective Nonsteroidal Mineralocorticoid Receptor Antagonist Protects From Rat Cardiorenal Injury
Peter Kolkhof et al.
JOURNAL OF CARDIOVASCULAR PHARMACOLOGY (2014)
The ARTS of third-generation mineralocorticoid receptor antagonists: achieving cardiovascular benefit with minimized renal side effects?
Johann Bauersachs
EUROPEAN HEART JOURNAL (2013)
Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: a randomized, double-blind trial
Bertram Pitt et al.
EUROPEAN HEART JOURNAL (2013)
Discovery of BAY 94-8862: A Nonsteroidal Antagonist of the Mineralocorticoid Receptor for the Treatment of Cardiorenal Diseases
Lars Baerfacker et al.
CHEMMEDCHEM (2012)
Rationale and design of ARTS: a randomized, double-blind study of BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease
Bertram Pitt et al.
EUROPEAN JOURNAL OF HEART FAILURE (2012)
Molecular pharmacology of the mineralocorticoid receptor: Prospects for novel therapeutics
Peter Kolkhof et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2012)
A double-blind, randomized study comparing the antihypertensive effect of eplerenone and spironolactone in patients with hypertension and evidence of primary aldosteronism
Hari K. Parthasarathy et al.
JOURNAL OF HYPERTENSION (2011)
Eplerenone in Patients with Systolic Heart Failure and Mild Symptoms.
Faiez Zannad et al.
NEW ENGLAND JOURNAL OF MEDICINE (2011)
A New Mode of Mineralocorticoid Receptor Antagonism by a Potent and Selective Nonsteroidal Molecule
Jerome Fagart et al.
JOURNAL OF BIOLOGICAL CHEMISTRY (2010)
Discovery of Novel Cyanodihydropyridines as Potent Mineralocorticoid Receptor Antagonists
Graciela B. Arhancet et al.
JOURNAL OF MEDICINAL CHEMISTRY (2010)
Renal aspirin: will all patients with chronic kidney disease one day take spironolactone?
Andrew S. Bomback et al.
NATURE CLINICAL PRACTICE NEPHROLOGY (2009)
Stroke therapy: Is spironolactone the holy grail?
Anne M. Dorrance
ENDOCRINOLOGY (2008)
Molecular mechanisms of mineralocorticoid receptor antagonism by eplerenone
X Hu et al.
MINI-REVIEWS IN MEDICINAL CHEMISTRY (2005)
Tolerability of spironolactone as adjunctive treatment for heart failure in patients over 75 years of age
C Dinsdale et al.
AGE AND AGEING (2005)
Pharmacokinetics and pharmacodynamics of mineralocorticoid blocking agents and their effects on potassium homeostasis
D Sica
HEART FAILURE REVIEWS (2005)
Mineralocorticoid receptors: Distribution and activation
JW Funder
HEART FAILURE REVIEWS (2005)
The evolution of aldosterone antagonists
SM Garthwaite et al.
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2004)
The 45-year story of the development of an anti-aldosterone more specific than spironolactone
JL Ménard
MOLECULAR AND CELLULAR ENDOCRINOLOGY (2004)
Rates of hyperkalemia after publication of the randomized aldactone evaluation study
DN Juurlink et al.
NEW ENGLAND JOURNAL OF MEDICINE (2004)
How prevalent is hyperkalemia and renal dysfunction during treatment with spironolactone in patients with congestive heart failure?
M Svensson et al.
JOURNAL OF CARDIAC FAILURE (2004)
Pharmacokinetics and metabolism of [14C]eplerenone after oral administration to humans
CS Cook et al.
DRUG METABOLISM AND DISPOSITION (2003)
Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction
B Pitt et al.
NEW ENGLAND JOURNAL OF MEDICINE (2003)
Aldosterone induces a vascular inflammatory phenotype in the rat heart
R Rocha et al.
AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY (2002)
Eplerenone, a selective aldosterone blocker, in mild-to-moderate hypertension
MH Weinberger et al.
AMERICAN JOURNAL OF HYPERTENSION (2002)
Activating mineralocorticoid receptor mutation in hypertension exacerbated by pregnancy
DS Geller et al.
SCIENCE (2000)
分享论文
